RxDoctor Payments Data

Dhruval Patel, MD

Nephrology · Wilmington, DENPI 1912101502

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $2,396 of the $2,869 with a category attached, or 83.5%. It is spread thinly across 26 manufacturers, the largest accounting for just 15.3% — the pattern of someone who eats at a lot of different presentations.

$2,869in general payments, 2019–2025

Across 129 payments — averaging $22.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$439
  • AstraZeneca$392
  • Mallinckrodt Hospital Products Inc.$335
  • OPKO Pharmaceuticals, LLC$298
  • Aurinia Pharma U.S., Inc.$247
  • Boehringer Ingelheim$174
  • plus $985 from 20 others

What the payments were for

  • Food & beverage$2,39684%
  • Education$47316%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,869 in reported general payments places this provider in the 55th percentile of 49 nephrology providers in Delaware.

See all nephrology providers in Delaware

Medicare billing

Part B allowed, 2024
$548,100
Medicare patients
935
Services billed
5,116

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol75$99,566
KerendiaFinerenone58$82,602
JardianceEmpagliflozin59$79,460
LokelmaSodium Zirconium Cyclosilicate15$21,882
Calcitriol95$1,524
Losartan Potassium115$1,261
Lisinopril108$788
Metoprolol Succinate44$762
Valsartan15$663
Potassium Chloride28$628
Amlodipine Besylate42$385
Hydralazine Hcl23$351
Carvedilol25$263
Allopurinol17$168
Furosemide39$159

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$392$121,44890 claims
BayerKerendia$439$82,60258 claims
Boehringer IngelheimJardiance$174$79,46059 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 49 nephrology providers in Delaware.

Other nephrology in Wilmington

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →